London, UK (CWBN)_ Pfizer CEO, Albert Bourla, stated that it is “not certain” if its COVID-19 vaccine developed together with Germany based, BioNTech, would prevent the transmission virus and that “it needs to be examined”, as per an NBC report from the 2nd of November.
The comment arrives just days after the UK became the world’s first country to formally authorise the vaccine for general use.
The Medicines and Healthcare Products Regulatory Agency (UK), said that the mRNA-based vaccine has shown 95 percent efficacy “irrespective of age, sex or race”, and it is safe for mass immunisations, starting with the high priority groups. The body assured “no corners cut” to approve it and the safety of citizens was a “first priority”.
It was reported that the UK has ordered up to 40 million doses of the vaccine for double-dose immunisation covering 20 million people. However the MHRA is still considering the logistics of the immunization process.
The regulator noted that the Pfizer-BioNTech vaccine is similar to other vaccines that are being trialled across the world “and the side effects are very low” with no specific precautions or tests required before inoculation.
